ATE516356T1 - Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung - Google Patents

Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung

Info

Publication number
ATE516356T1
ATE516356T1 AT02806841T AT02806841T ATE516356T1 AT E516356 T1 ATE516356 T1 AT E516356T1 AT 02806841 T AT02806841 T AT 02806841T AT 02806841 T AT02806841 T AT 02806841T AT E516356 T1 ATE516356 T1 AT E516356T1
Authority
AT
Austria
Prior art keywords
lysostaphin
staphylolytic
supported
improved
effect
Prior art date
Application number
AT02806841T
Other languages
English (en)
Inventor
Jeffrey Stinson
Lioubov Grinberg
Andrew Lees
James Mond
John Kokai-Kun
Original Assignee
Biosynexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosynexus Inc filed Critical Biosynexus Inc
Application granted granted Critical
Publication of ATE516356T1 publication Critical patent/ATE516356T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02806841T 2001-12-21 2002-12-23 Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung ATE516356T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34180401P 2001-12-21 2001-12-21
PCT/US2002/040924 WO2003082184A2 (en) 2001-12-21 2002-12-23 Truncated lysostaphin molecule with enhanced staphylolytic activity

Publications (1)

Publication Number Publication Date
ATE516356T1 true ATE516356T1 (de) 2011-07-15

Family

ID=28675229

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02806841T ATE516356T1 (de) 2001-12-21 2002-12-23 Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung

Country Status (7)

Country Link
US (1) US20050118159A1 (de)
EP (1) EP1465990B1 (de)
JP (1) JP4348194B2 (de)
AT (1) ATE516356T1 (de)
AU (1) AU2002367820B2 (de)
CA (1) CA2469720A1 (de)
WO (1) WO2003082184A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005067887A2 (en) * 2004-03-24 2005-07-28 Actavis Group Formulations of ramipril
CN100475965C (zh) * 2005-07-22 2009-04-08 上海高科联合生物技术研发有限公司 一种大肠杆菌高效外分泌表达溶葡萄球菌酶的方法
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
CN105579053B (zh) * 2013-08-06 2021-08-31 达特茅斯学院理事会 非糖基化溶葡球菌素变体蛋白
CN106795506B (zh) 2014-05-14 2020-11-27 达特茅斯学院理事会 去免疫化溶葡萄球菌酶和使用方法
CN106148254B (zh) * 2015-03-26 2019-11-12 南京华贞生物医药科技有限公司 一种用于减肥降脂的转化体及其构建方法与应用
CN107916244A (zh) * 2017-06-20 2018-04-17 江西嘉博生物工程有限公司 一种表达溶葡球菌素基因的重组乳酸乳球菌的构建方法及应用
MX2020005875A (es) * 2017-12-05 2020-10-08 Bioplx Inc Métodos y composiciones para prevenir la infección microbiana.
CN115942932A (zh) 2020-03-19 2023-04-07 迈克瑞欧斯人体健康有限公司 感兴趣的稳定蛋白
CN115976158B (zh) * 2023-03-16 2023-07-04 百葵锐(天津)生物科技有限公司 一种裂解酶酶活性测定方法
WO2024241070A1 (en) 2023-05-22 2024-11-28 L'oreal Cosmetic composition comprising an endolysin and a polyvinyl alcohol
WO2024246325A1 (en) 2023-06-02 2024-12-05 L'oreal Cosmetic composition comprising an endolysin derived from a staphylococcus aureus phage and an aromatic alcohol
FR3152395B1 (fr) 2023-08-28 2026-06-26 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et la 4-hydroxyacetophenone
FR3149203B1 (fr) 2023-06-02 2026-03-13 Oreal Composition anhydre comprenant une endolysine et de l’hydroxypropylmethylcellulose et/ou du pullulane
FR3149205B1 (fr) 2023-06-02 2026-04-24 Oreal Composition cosmétique comprenant une endolysine et un agent de charge organique
FR3149209B1 (fr) 2023-06-02 2026-04-03 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique
FR3149204B1 (fr) 2023-06-02 2026-02-13 Oreal Composition cosmétique comprenant une endolysine et un tensioactif non ionique comprenant un résidu carbohydrate
FR3149206B1 (fr) 2023-06-02 2026-03-13 Oreal Composition cosmétique aqueuse comprenant une endolysine et du tréhalose
FR3149207B1 (fr) 2023-06-02 2026-03-13 Oreal Composition cosmétique comprenant une endolysine et un composé de formule (I)
FR3149202B1 (fr) 2023-06-02 2026-04-10 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et une huile.
FR3149208B1 (fr) 2023-06-02 2026-03-20 Oreal Composition cosmétique, notamment aqueuse, comprenant une endolysine et un pullulane
FR3152393B1 (fr) 2023-08-28 2026-04-24 Oreal Composition cosmétique comprenant une endolysine dérivée d’un phage de Staphylococcus aureus et une charge minérale
FR3152394B1 (fr) 2023-08-28 2026-04-24 Oreal Composition cosmétique comprenant une endolysine et des particules d’aérogel de silice hydrophobe
FR3152396B1 (fr) 2023-08-28 2026-05-22 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un polyhydroxyalcane
WO2025093666A1 (en) 2023-11-01 2025-05-08 University Of Copenhagen Treatment of lymphoma
WO2026052743A1 (en) 2024-09-04 2026-03-12 Micreos Human Health B.V. Reduction of trans-epidermal water loss by a polypeptide with antibacterial properties

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931390A (en) * 1986-04-16 1990-06-05 Public Health Research Institute Of The City Of New York, Inc. Expression of the cloned lysostaphin gene
US5011772A (en) * 1988-02-05 1991-04-30 Public Health Research Institute Of The City Of N.Y. High yield protein production system
DE4425645A1 (de) * 1994-07-20 1996-02-22 Mueller Karl & Co Kg Deletiertes Lysostaphingen von Staphylococcus simulans
US6028051A (en) * 1997-07-23 2000-02-22 Ambi Inc. Method for the treatment of staphylococcal disease
CA2211293A1 (en) * 1997-07-23 1999-01-23 Immunova Ltee Recombinant lysostaphin analogs
US6248558B1 (en) * 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
AU4706799A (en) * 1998-06-22 2000-01-10 University Of Vermont And State Agricultural College, The Treatment of (staphylococcus) infections
ATE430799T1 (de) * 1999-10-19 2009-05-15 Bharat Biotech International L Expression von rekombinantem, reifem lysostaphin
AU2001256350A1 (en) * 2000-05-12 2001-11-20 Bayer Aktiengesellschaft Regulation of human lysostaphin-like protease

Also Published As

Publication number Publication date
CA2469720A1 (en) 2003-10-09
EP1465990A4 (de) 2006-06-28
JP4348194B2 (ja) 2009-10-21
EP1465990B1 (de) 2011-07-13
WO2003082184A3 (en) 2004-07-22
AU2002367820A1 (en) 2003-10-13
AU2002367820B2 (en) 2007-11-01
WO2003082184A2 (en) 2003-10-09
EP1465990A2 (de) 2004-10-13
US20050118159A1 (en) 2005-06-02
JP2005519628A (ja) 2005-07-07

Similar Documents

Publication Publication Date Title
EP1465990A4 (de) Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung
ATE360031T1 (de) Chimäre proteine und anwendungen
BR0110573A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização do composto e processo para o tratamento profilático ou terapêutico e para a preparação do composto
AR032231A1 (es) Nuevas proteinas insecticidas de bacillus thuringiensis
BR0108173A (pt) Composições farmacêuticas de toxina de botulina
ATE552854T1 (de) Gezielte biozide
NO20024157L (no) Kasein-avledete peptider og anvendelser derav i terapi
CY1117401T1 (el) Πρωτεϊνες συντηξης αλβουμινης
DE60011100D1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol-verbindungen
EA201001212A8 (ru) Лечение микробных инфекций
ATE476495T1 (de) Bazillus thuringiensis und dessen insektizide proteine
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
NO20082628L (no) Stabile proteinformuleringer
CY1118930T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
ATE556092T1 (de) Mittel zur diagnose und therapie von ctcl
EE200200625A (et) Orto-asendatud antraniilhappeamiidid ja nende kasutamine ravimitena
ATE310089T1 (de) Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
DE60136381D1 (de) Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
DE60034879T8 (de) Lantibiotikum
ATE313562T1 (de) Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins
WO2002030964A3 (en) Comparative ligand mapping from mhc positive cells
BR0009170A (pt) ácidos nucléicos akt, polipeptìdeos e uso dos mesmos
WO2009037183A3 (de) Nukleinsäurehaltige kosmetische und/oder pharmazeutische zubereitung zur induktion antimikrobieller peptide in epithelialen deckgeweben

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties